Tscan Therapeutics Inc

-0.01 (-0.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)117.12M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$3.48 Million
Adjusted EPS-$0.59
See more estimates
10-Day MA$7.33
50-Day MAN/A
200-Day MAN/A
See more pivots

Tscan Therapeutics Inc Stock, NASDAQ:TCRX

830 Winter Street, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.399.9500
Number of Employees:


TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.